Plasmodium falciparum merozoite surface protein 1 (MSP1-19) (MSP1-19)

Plasmodium falciparum merozoite surface protein 1 (MSP1) is a major surface protein of the malaria parasite's blood-stage form, synthesized as a large ~200 kDa precursor (UniProt: P04932). The 19-kDa C-terminal region, known as MSP1-19, is the final product of sequential proteolytic processing and remains attached to the merozoite surface via a glycosylphosphatidylinositol (GPI) anchor during erythrocyte invasion (PubMed: 10551350). This fragment consists of two cysteine-rich epidermal growth factor (EGF)-like domains that are essential for the parasite's ability to successfully enter host red blood cells (PubMed: 15567131). Because MSP1-19 is carried into the host cell and is relatively conserved across different parasite strains, it has been a primary target for blood-stage malaria vaccine development (PubMed: 11748106). Antibodies directed against MSP1-19 can inhibit the secondary processing of the MSP1-42 precursor or directly block the invasion process, thereby reducing parasite burden (PubMed: 9712300). Clinical trials have evaluated various recombinant MSP1-19 formulations, though achieving high and sustained titers of protective antibodies remains a significant challenge in the field (PubMed: 16254652).

Other names

Merozoite surface protein 1 19 kDa fragmentPfMSP1-19MSP-1(19)19-kDa C-terminal region of MSP1Merozoite surface antigen 1

Induction of invasion-inhibitory antibodies that prevent the parasite from entering host erythrocytes by sterically hindering the secondary proteolytic processing of the MSP1-42 precursor or by directly blocking the interaction between the merozoite and the host cell membrane (PubMed: 9712300).